Accelerating the development of a therapeutic vaccine for human Chagas disease: Rationale and prospects

Expert Review of Vaccines

Volumn 11, Issue 9, 2012, Pages 1043-1055

  Dumonteil, Eric ^a   Bottazzi, Maria Elena ^b   Zhan, Bin ^b   Heffernan, Michael J ^b   Jones, Kathryn ^b   Valenzuela, Jesus G ^c   Kamhawi, Shaden ^c   Ortega, Jaime ^d   De Leon Rosales, Samuel Ponce ^e   Lee, Bruce Y ^f   Bacon, Kristina M ^f   Fleischer, Bernhard ^g   Slingsby, B T ^h   Cravioto, Miguel Betancourt ⁱ   Tapia Conyer, Roberto ⁱ   Hotez, Peter J ^b  

^a UNIVERSIDAD AUTÓNOMA DE YUCATÁN   (Mexico)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d DEPARTAMENTO DE FÍSICA   (Mexico)

^e Laboratorios de Biológicos y Reactivos de Mexico BIRMEX   (Mexico)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^h EISAI CO LTD   (Japan)

ⁱ Instituto Carlos Slim de la Salud (ICSS)   (Mexico)

Author keywords

Chagas disease; Mesoamerica; Mexico; Tc24; therapeutic vaccine; Trypanosoma cruzi; trypomastigote antigen; TSA 1; vaccine

Indexed keywords

ADJUVANT; ANTIGEN; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; NIFURTIMOX; TC24 ANTIGEN; TOLL LIKE RECEPTOR AGONIST; TRYPANOSOMA CRUZI VACCINE; TSA 1 ANTIGEN; UNCLASSIFIED DRUG;

ANTIGENICITY; AUTOIMMUNITY; CARDITIS; CHAGAS DISEASE; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; ECG ABNORMALITY; EDEMA; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; TRYPANOSOMA CRUZI; URTICARIA;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; CHAGAS DISEASE; HUMANS; PROTOZOAN VACCINES; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 84869415260     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.85     Document Type: Review

References (75)

1. Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR. The neglected tropical diseases of Latin America and the Caribbean: A review of disease burden and distribution and a roadmap for control and elimination. Plos Negl. Trop. Dis. 2(9), e300 (2008
2. WHO. First WHO report on neglected tropical diseases: Working to overcome the impact of neglected tropical diseases. WHO, Geneva, Switzerland (2010
3. Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR. The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. Plos Negl. Trop. Dis. 4(12), e916 (2010
4. Hotez PJ, Dumonteil E, Heffernan MJ, Bottazzi ME. Innovation for "the bottom 100 million": Eliminating neglected tropical diseases in the Americas through mass drug administration and new vaccines for hookworm and Chagas disease. Adv. Exp. Biol. Med. (2012) (In Press
5. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 375(9723), 1388-1402 (2010
6. Hotez PJ, Bottazzi ME, Dumonteil E et al. Texas and Mexico: Sharing a legacy of poverty and neglected tropical diseases. Plos Negl. Trop. Dis.6(3), e1497 (2012
7. Cruz-Reyes A, Pickering-López JM. Chagas disease in Mexico: An analysis of geographical distribution during the past 76 years- A review. Mem. Inst. Oswaldo Cruz 101(4), 345-354 (2006
8. Ramos-Ligonio A, López-Monteon A, Guzmán-Gómez D, Rosales-Encina JL, Limón-Flores Y, Dumonteil E. Identification of a hyperendemic area for Trypanosoma cruzi infection in central Veracruz, Mexico. Am. J. Trop. Med. Hyg. 83(1), 164-170 (2010
9. Bern C, Montgomery SP. An estimate of the burden of Chagas disease in the United States. Clin. Infect. Dis. 49(5), e52-e54 (2009
10. Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and Chagas' disease in the United States. Clin. Microbiol. Rev. 24(4), 655-681 (2011
11. Hotez PJ. Neglected infections of poverty in the United States of America. Plos Negl. Trop. Dis. 2, e279 (2008
12. Hotez PJ, Gurwith M. Europe's neglected infections of poverty. Int. J. Infect. Dis. 15(9), e611-e619 (2011
13. Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 115(1-2), 22-27 (2010
14. Schmunis GA, Yadon ZE. Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop. 115(1-2), 14-21 (2010
15. Theiler RN, Rasmussen SA, Treadwell TA, Jamieson DJ. Emerging and zoonotic infections in women. Infect. Dis. Clin. North Am. 22(4), 755-72, vii (2008
16. Siriano Lda R, Luquetti AO, Avelar JB, Marra NL, de Castro AM. Chagas disease: Increased parasitemia during pregnancy detected by hemoculture. Am. J. Trop. Med. Hyg. 84(4), 569-574 (2011
17. Pérez-López FR, Chedraui P. Chagas disease in pregnancy: A non-endemic problem in a globalized world. Arch. Gynecol. Obstet. 282(6), 595-599 (2010
18. Buekens P, Almendares O, Carlier Y et al. Mother-to-child transmission of Chagas' disease in North America: Why don't we do more? Matern. Child Health J. 12(3), 283-286 (2008
19. Roca C, Pinazo MJ, Lopez-Chejade P et al. Chagas disease among the Latin American adult population attending in a primary care center in Barcelona. Plos Negl. Trop. Dis. 26, e1135 (2011
20. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int. J. Parasitol. 31(5-6), 550-554 (2001
21. Plessman Camargo E. Perspectives of vaccination in Chagas disease revisited. Mem. Inst. Oswaldo Cruz 104 (SUPPL1), 275-280 (2009
22. Lescure FX, Le Loup G, Freilij H et al. Chagas disease: Changes in knowledge and management. Lancet Infect. Dis. 10(8), 556-570 (2010
23. Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N. Engl. J. Med. 364(26), 2527-2534 (2011
24. Pérez-Molina JA, Pérez-Ayala A, Moreno S, Fernández-González MC, Zamora J, López-Velez R. Use of benznidazole to treat chronic Chagas' disease: A systematic review with a meta-analysis. J. Antimicrob. Chemother. 64(6), 1139-1147 (2009
25. Marin-Neto, Rassi A Jr, Morillo CA et al, on behalf of BENEFIT Investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas cardiomyopathy: The Benznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT). Am. Heart J. 156, 37-43 (2008
26. Sarli Issa V, Alcides Bocchi E. Antitrypanosomal agents: Treatment or threat? Lancet 376, 768-769 (2010
27. Pinazo MJ, Muñoz J, Posada E et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob. Agents Chemother. 54(11), 4896-4899 (2010
28. Viotti R, Vigliano C, Lococo B et al. Side effects of benznidazole as treatment in chronic Chagas disease: Fears and realities. Expert Rev. Anti. Infect. Ther. 7(2), 157-163 (2009
29. Castillo-Riquelme M, Guhl F, Turriago B et al. The costs of preventing and treating chagas disease in Colombia. Plos Negl. Trop. Dis. 2(11), e336 (2008
30. Vallejo M, Montenegro P, Reyes PA. How much does the medical treatment of chronic Chagas cardiopathy cost? Direct costs in a cardiology hospital. Arch. Cardiol. Mex. 72(2), 129-137 (2002
31. APTW. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des. Devel. Ther. 4, 243-253 (2010
32. Buckner FS, Navabi N. Advances in Chagas disease drug development: 2009-2010. Curr. Opin. Infect. Dis. 23(6), 609-616 (2010
33. Hotez PJ, Dumonteil E, Woc-Colburn L et al. Chagas disease: 'The New HIV/ AIDS of the Americas'. Plos Negl. Trop. Dis. 6(5), e1498 (2012
34. Cazorla SI, Frank FM, Malchiodi EL. Vaccination approaches against Trypanosoma cruzi infection. Expert Rev. Vaccines 8(7), 921-935 (2009
35. Vázquez-Chagoyán JC, Gupta S, Garg NJ. Vaccine development against Trypanosoma cruzi and Chagas disease. Adv. Parasitol. 75, 121-146 (2011
36. Quijano-Hernandez I, Dumonteil E. Advances and challenges towards a vaccine against Chagas disease. Hum. Vaccin. 7(11), 1184-1191 (2011
37. Lee BY, Bacon KM, Wateska AR et al. Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum. Vaccines Immunther. 8(9), 1293-1301 (2012
38. Dumonteil E, Escobedo-Ortegon J, Reyes-Rodriguez N, Arjona-Torres A, Ramirez-Sierra MJ. Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice. Infect. Immun. 72(1), 46-53 (2004
39. Zapata-Estrella H, Hummel-Newell C, Sanchez-Burgos G et al. Control of Trypanosoma cruzi infection and changes in T-cell populations induced by a therapeutic DNA vaccine in mice. Immunol. Lett. 103(2), 186-191 (2006
40. Sanchez-Burgos G, Mezquita-Vega RG, Escobedo-Ortegon J et al. Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice. FEMS Immunol. Med. Microbiol. 50(3), 333-341 (2007
41. Dumonteil E. DNA vaccines against protozoan-parasites: Advances and challenges. J. Biomed. Biotechnol. 2007, 90520 (2007
42. Quijano-Hernandez IA, Bolio-González ME, Rodríguez-Buenfil JC, Ramirez-Sierra MJ, Dumonteil E. Therapeutic DNA vaccine against Trypanosoma cruzi infection in dogs. Ann. NY Acad. Sci. 1149, 343-346 (2008
43. Dumonteil E. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect. Genet. Evol. 9(6), 1075-1082 (2009
44. Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL et al. Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: Role of CD4+ and CD8+ T cells. Vaccine 28(46), 7414-7419 (2010
45. Ishizaka ST, Hawkins LD. E6020: A synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev. Vaccines 6(5), 773-784 (2007
46. Baudner BC, Ronconi V, Casini D et al. MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm. Res. 26(6), 1477-1485 (2009
47. Wizel B, Garg N, Tarleton RL. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect. Immun. 66(11), 5073-5081 (1998). using TSA-1.
48. Garg N, Tarleton RL. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect. Immun. 70(10), 5547-5555 (2002
49. Gupta S, Garg NJ. Prophylactic efficacy of TcVac2 against Trypanosoma cruzi in mice. Plos Negl. Trop. Dis. 4(8), e797 (2010
50. Aparicio-Burgos JE, Ochoa-García L, Zepeda-Escobar JA et al. Testing the efficacy of a multi-component DNAprime/ DNA-boost vaccine against Trypanosoma cruzi infection in dogs. Plos Negl. Trop. Dis. 5(5), e1050 (2011
51. Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB. Clinical applications of DNA vaccines: Current progress. Clin. Infect. Dis. 53(3), 296-302 (2011
52. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant- 'the long and winding road'. Drug Discov. Today 14(11-12), 541-551 (2009
53. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9(9), 1095-1107 (2010
54. Heffernan MJ, Kasturi SP, Yang SC, Pulendran B, Murthy N. The stimulation of CD8+ T cells by dendritic cells pulsed with polyketal microparticles containing ion-paired protein antigen and poly(inosinic acid)-poly(cytidylic acid). Biomaterials 30(5), 910-918 (2009
55. Heffernan MJ, Zaharoff DA, Fallon JK, Schlom J, Greiner JW. In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines. Biomaterials 32(3), 926-932 (2011
56. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV. Viral vectors as vaccine platforms: Deployment in sight. Curr. Opin. Immunol. 23(3), 377-382 (2011
57. Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. Plos One 6(2), e14626 (2011
58. Hill AV, Reyes-Sandoval A, O'Hara G et al. Prime-boost vectored malaria vaccines: Progress and prospects. Hum. Vaccin. 6(1), 78-83 (2010
59. Hotez P. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff. (Millwood) 30(6), 1080-1087 (2011
60. Lieke T, Graefe SE, Klauenberg U, Fleischer B, Jacobs T. NK cells contribute to the control of Trypanosoma cruzi infection by killing free parasites by perforin-independent mechanisms. Infect. Immun. 72(12), 6817-6825 (2004
61. Lieke T, Steeg C, Graefe SE, Fleischer B, Jacobs T. Interaction of natural killer cells with Trypanosoma cruzi-infected fibroblasts. Clin. Exp. Immunol. 145(2), 357-364 (2006
62. Jacobs T, Erdmann H, Fleischer B. Molecular interaction of Siglecs (sialic acid-binding Ig-like lectins) with sialylated ligands on Trypanosoma cruzi. Eur. J. Cell Biol. 89(1), 113-116 (2010
63. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J. Pharm. Sci. doi:10.1002/ jps.22618 (2011) (Epub ahead of print
64. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simões MV. Pathogenesis of chronic Chagas heart disease. Circulation 115(9), 1109-1123 (2007
65. Gutierrez FR, Guedes PM, Gazzinelli RT, Silva JS. The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunol. 31(11), 673-685 (2009
66. Machado FS, Tyler KM, Brant F, Esper L, Teixeira MM, Tanowitz HB. Pathogenesis of Chagas disease: Time to move on. Front. Biosci. (Elite Ed.) 4, 1743-1758 (2012
67. Zabalgoitia M, Ventura J, Anderson L, Williams JT, Carey KD, Vandeberg JL. Electrocardiographic findings in naturally acquired chagasic heart disease in nonhuman primates. J. Electrocardiol. 36(2), 155-160 (2003
68. Zabalgoitia M, Ventura J, Anderson L, Carey KD, Williams JT, Vandeberg JL. Morphologic and functional characterization of Chagasic heart disease in non-human primates. Am. J. Trop. Med. Hyg. 68(2), 248-252 (2003
69. Ramírez JD, Guhl F, Rendón LM, Rosas F, Marin-Neto JA, Morillo CA. Chagas cardiomyopathy manifestations and Trypanosoma cruzi genotypes circulating in chronic Chagasic patients. Plos Negl. Trop. Dis. 4(11), e899 (2010
70. Garcia-Alvarez A, Sitges M, Pinazo MJ et al. Chagas cardiomyopathy: The potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage. Plos Negl. Trop. Dis. 4(9), e826 (2010
71. Ndao M, Spithill TW, Caffrey R et al. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. J. Clin. Microbiol. 48(4), 1139-1149 (2010
72. Saravia SG, Haberland A, Bartel S et al. Cardiac troponin T measured with a highly sensitive assay for diagnosis and monitoring of heart injury in chronic Chagas disease. Arch. Pathol. Lab. Med. 135(2), 243-248 (2011
73. Laucella SA, Mazliah DP, Bertocchi G et al. Changes in Trypanosoma cruzi-specific immune responses after treatment: Surrogate markers of treatment efficacy. Clin. Infect. Dis. 49(11), 1675-1684 (2009
74. Lorena VM, Lorena IM, Braz SC et al. Cytokine levels in serious cardiopathy of Chagas disease after in vitro stimulation with recombinant antigens from Trypanosoma cruzi. Scand. J. Immunol. 72(6), 529-539 (2010
75. Wen JJ, Zago MP, Nunez S, Gupta S, Nunez Burgos F, Garg NJ. Serum proteomic signature of human chagasic patients for the identification of novel protein biomarkers of disease. Mol. Cell. Proteomics doi:10.1074/mcp.M112.017640 (2012) (Epub ahead of print